Charles Schwab’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Charles Schwab’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-26	Closed	-$18.3K	–	3574
2023 Q3	$18.3K	Buy	26 +16	+160%	+$68.6K	﹤0.01%	3519
2023 Q2	$46.8K	Hold	10	–	–	﹤0.01%	3428
2023 Q1	$27.1K	Hold	10	–	–	﹤0.01%	3465
2022 Q4	$26.6K	Hold	10	–	–	﹤0.01%	3470
2022 Q3	$41K	Hold	10	–	–	﹤0.01%	3378
2022 Q2	$27K	Sell	10 -59	-86%	-$154K	﹤0.01%	3497
2022 Q1	$222K	Buy	69 +5	+8%	+$21.5K	﹤0.01%	3288
2021 Q4	$401K	Hold	64	–	–	﹤0.01%	3221
2021 Q3	$593K	Buy	64 +12	+23%	+$103K	﹤0.01%	3087
2021 Q2	$528K	Buy	52 +46	+767%	+$756K	﹤0.01%	3156
2021 Q1	$123K	Buy	+6	New	+$70K	﹤0.01%	3366

Other funds holding SEEL

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Charles Schwab's SEEL Position: Q4 2023 in Review

Charles Schwab sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2023, closing a stake of 26 shares — an estimated $18.3K sold.

Charles Schwab first reported a position in SEEL in Q1 2021 and held it in 11 quarters. The position peaked at $593K in Q3 2021. 32 funds tracked by Wall St. Rank hold SEEL as of Q4 2023.

Charles Schwab reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Charles Schwab sold 26 Seelos Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $18.3K.
Charles Schwab first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2021 and held it in 11 quarters.
Charles Schwab's Seelos Therapeutics, Inc. Common Stock position peaked at $593K in Q3 2021.
32 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Charles Schwab's 13F filing for Q4 2023, filed 6 Feb 2024.